Study of Durvalumab Given with Chemoradiation Therapy in Patients with Unresectable Non-small Cell Lung Cancer

Study identifier:D933KC00001

ClinicalTrials.gov identifier:NCT03519971

EudraCT identifier:2017-004397-34

CTIS identifier:2024-515321-29-00

Recruitment Complete

Official Title

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel, Pemetrexed/ Cisplatin, Pemetrexed/ Carboplatin

Sex

All

Actual Enrollment

328

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 29 Mar 2018
Primary Completion Date: 07 Sept 2023
Estimated Study Completion Date: 31 Oct 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria